Cargando…
Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are no...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817714/ https://www.ncbi.nlm.nih.gov/pubmed/31749616 http://dx.doi.org/10.2147/IJN.S218488 |
_version_ | 1783463482072498176 |
---|---|
author | Mühlberger, Marina Janko, Christina Unterweger, Harald Friedrich, Ralf P Friedrich, Bernhard Band, Julia Cebulla, Nadine Alexiou, Christoph Dudziak, Diana Lee, Geoffrey Tietze, Rainer |
author_facet | Mühlberger, Marina Janko, Christina Unterweger, Harald Friedrich, Ralf P Friedrich, Bernhard Band, Julia Cebulla, Nadine Alexiou, Christoph Dudziak, Diana Lee, Geoffrey Tietze, Rainer |
author_sort | Mühlberger, Marina |
collection | PubMed |
description | PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are not infiltrated and “immune excluded” tumors are only infiltrated in the peripheral tumor tissue. Checkpoint inhibitors provide new therapeutic options for “hot” tumors by triggering the immune response of T cells. In order to enable this for cold tumors as well, T cells must be enriched in the tumor. Therefore, we use the principle of magnetic targeting to guide T cells loaded with citrate-coated superparamagnetic iron oxide nanoparticles (SPION(Citrate)) to the tumor by an externally applied magnetic field. METHODS: SPION(Citrate) were produced by alkaline coprecipitation of iron(II) and iron(III) chloride and in situ coating with sodium citrate. The concentration-dependent cytocompatibility of the particles was determined by flow cytometry and blood stability assays. Atomic emission spectroscopy was used for the quantification of the particle uptake into T lymphocytes. The attractability of the loaded cells was observed by live-cell imaging in the presence of an externally applied magnetic field. RESULTS: SPION(Citrate) displayed good cytocompatibility to T cells and did not show any sign of aggregation in blood. Finally, SPION(Citrate)-loaded T cells were strongly attracted by a small external magnet. CONCLUSION: T cells can be “magnetized” by incorporation of SPION(Citrate) for magnetic targeting. The production of the particle-cell hybrid system is straightforward, as the loading process only requires basic laboratory devices and the loading efficiency is sufficient for cells being magnetically controllable. For these reasons, SPION(Citrate) are potential suitable candidates for magnetic T cell targeting. |
format | Online Article Text |
id | pubmed-6817714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68177142019-11-20 Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy Mühlberger, Marina Janko, Christina Unterweger, Harald Friedrich, Ralf P Friedrich, Bernhard Band, Julia Cebulla, Nadine Alexiou, Christoph Dudziak, Diana Lee, Geoffrey Tietze, Rainer Int J Nanomedicine Original Research PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are not infiltrated and “immune excluded” tumors are only infiltrated in the peripheral tumor tissue. Checkpoint inhibitors provide new therapeutic options for “hot” tumors by triggering the immune response of T cells. In order to enable this for cold tumors as well, T cells must be enriched in the tumor. Therefore, we use the principle of magnetic targeting to guide T cells loaded with citrate-coated superparamagnetic iron oxide nanoparticles (SPION(Citrate)) to the tumor by an externally applied magnetic field. METHODS: SPION(Citrate) were produced by alkaline coprecipitation of iron(II) and iron(III) chloride and in situ coating with sodium citrate. The concentration-dependent cytocompatibility of the particles was determined by flow cytometry and blood stability assays. Atomic emission spectroscopy was used for the quantification of the particle uptake into T lymphocytes. The attractability of the loaded cells was observed by live-cell imaging in the presence of an externally applied magnetic field. RESULTS: SPION(Citrate) displayed good cytocompatibility to T cells and did not show any sign of aggregation in blood. Finally, SPION(Citrate)-loaded T cells were strongly attracted by a small external magnet. CONCLUSION: T cells can be “magnetized” by incorporation of SPION(Citrate) for magnetic targeting. The production of the particle-cell hybrid system is straightforward, as the loading process only requires basic laboratory devices and the loading efficiency is sufficient for cells being magnetically controllable. For these reasons, SPION(Citrate) are potential suitable candidates for magnetic T cell targeting. Dove 2019-10-24 /pmc/articles/PMC6817714/ /pubmed/31749616 http://dx.doi.org/10.2147/IJN.S218488 Text en © 2019 Mühlberger et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Mühlberger, Marina Janko, Christina Unterweger, Harald Friedrich, Ralf P Friedrich, Bernhard Band, Julia Cebulla, Nadine Alexiou, Christoph Dudziak, Diana Lee, Geoffrey Tietze, Rainer Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title | Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title_full | Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title_fullStr | Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title_full_unstemmed | Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title_short | Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy |
title_sort | functionalization of t lymphocytes with citrate-coated superparamagnetic iron oxide nanoparticles for magnetically controlled immune therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817714/ https://www.ncbi.nlm.nih.gov/pubmed/31749616 http://dx.doi.org/10.2147/IJN.S218488 |
work_keys_str_mv | AT muhlbergermarina functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT jankochristina functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT unterwegerharald functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT friedrichralfp functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT friedrichbernhard functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT bandjulia functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT cebullanadine functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT alexiouchristoph functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT dudziakdiana functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT leegeoffrey functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy AT tietzerainer functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy |